Sherman Oaks, CA – April 16, 2021 – T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that management will present virtually at the following upcoming webinar and healthcare conference:
Beacon Targeted Therapies’ Cell Therapies-Frontiers in Solid Tumor Treatment
- Gang Zeng, Chief Executive Officer, will participate the fireside panel discussion on Tuesday, April 20, 2021 at 12:00 p.m. (EDT). Dr. Zeng will cover general topics of adoptive cell therapy, including opportunities to overcome current challenges in treating solid tumors.
TCR-based Therapies Summit
- Erika von Euw, Senior Director of Translational Research, will lead a workshop on Tuesday, June 8, at 9:30 a.m. (EDT), titled “Development of Novel TCRs Derived from Responding Patients.”
- Gang Zeng, will give a presentation on Tuesday, June 8, at 3:00 p.m. (EDT), titled “Leveraging the Insights Gained from TIL Therapy to Improve Solid Tumor Immunotherapy”.
About T-Cure Bioscience, Inc.
T-Cure Bioscience, Inc. is an innovative immuno-oncology company committed to delivering effective and durable cell therapies for the treatment of cancer. The Company focuses on isolating high avidity TCR that can be used to engineer a patient’s T cells to effectively target and destroy solid tumors. The Company maintains a pipeline of TCR under clinical and pre-clinical development targeting HERV-E, KK-LC-1, NY-ESO-1 and other antigens associated with solid tumors of significant unmet medical needs, including kidney cancer, breast cancer, lung cancer, gastric cancer, ovarian cancer, liver cancer, pancreatic cancer, sarcoma, and glioblastoma. More information is available at www.T-Cure.com.
T-Cure Bioscience, Inc. IR & Media Contact
Rutland Baker